ONS has released the the Quality Improvement Registry, a qualified clinical data registry (QCDR) that applies to the Physician Quality Reporting System (PQRS). The registry focuses on the care of patients receiving intravenous chemotherapy in the ambulatory setting and on aspects of high-quality care in the first year of post-treatment survivorship for patients with breast cancer.
Search Results for "outcomes"
ONS Launches New Registry to Benchmark and Improve Patient Outcomes
Thursday, January 15, 2015
The Oncology Nursing Society (ONS) has launched the ONS Quality Improvement Registry, a qualified clinical data registry (QCDR) that practices can use to benchmark and improve patient outcomes. A QCDR enables the collection and submission of Physician Quality Reporting Systems (PQRS) quality measures data on behalf of eligible professionals, physicians, advanced practice nurses, and other clinicians who can independently bill Medicare.
ONS quality measures, developed and tested through a contract with The Joint Commission, supported through a grant to the ONS Foundation by the Breast Cancer Fund of the National Philanthropic Trust, are included in the registry.
The ONS Quality Improvement Registry is one of only 36 QCDRs approved nationally by the Centers for Medicare and Medicaid Services (CMS) and is offered through CECity®, health care’s leading provider of cloud-based registry platforms for performance improvement, value-based payment, and professionalism. The registry collects medical and clinical data for the purpose of patient and disease tracking to foster improvement in the quality of care provided to patients. Providers who successfully submit quality data to CMS under the PQRS reporting program are eligible to seek incentive payments and avoid payment penalties. The CMS-approved quality measures available only through the ONS Quality Improvement Registry can also be used for PQRS reporting.
“Registering and using the ONS Quality Improvement Registry will enable participants to use ONS’s quality measures to improve their practices through benchmarking their results with similar practices. The registry links directly to ONS resources which can help improve performance,” said Brenda Nevidjon, RN, MSN, FAAN, chief executive officer of ONS. “Participating in a QCDR advances the provision of quality cancer care, which is a central focus of ONS’s mission."
Register today for the ONS Quality Improvement Registry and find out how well your institution handles ambulatory chemotherapy and post-treatment care for breast cancer survivors.
CECity is the healthcare industry's leading provider of cloud-based registry solutions that address the "3 Ps" driven by healthcare reform: Pay for Value Reporting, Performance Improvement, and Professional Certification. CECity combines its unique registry and big data analytics platform with education and improvement interventions from world-class partners, to help all stakeholders answer the most important question, "How Do We Improve?" Since 1997, leading organizations across health care have counted on CECity to power and scale their high-stakes performance measurement, management, reporting, and improvement solutions as part of a global learning health system model for practice-based safety and quality improvement. CECity was one of the first PQRS registries qualified by CMS in 2008 and is widely recognized as the #1 cloud-based PQRS registry today. CECity powers more than 25% of the nation’s QCDRs in partnership with leaders in quality and is the exclusive performance assessment organization for the Bridges to Excellence program. Learn more at www.cecity.com.
ONS is a professional association of more than 35,000 members committed to promoting excellence in oncology nursing and the transformation of cancer care. Since 1975, ONS has provided a professional community for oncology nurses, developed evidence-based education programs and treatment information, and advocated for patient care, all in an effort to improve quality of life and outcomes for patients with cancer and their families.